The Expression and Clinicopathological Significance of BRAF V600E and Mucin 6 in Intrahepatic Cholangiocarcinoma: A Retrospective Study.

IF 0.9 4区医学 Q4 PATHOLOGY

International Journal of Surgical Pathology Pub Date : 2025-04-01 Epub Date: 2024-09-08 DOI:10.1177/10668969241266930

Shurui Wu, Meihong Wang, Qinghai Zhou, Haowen Tang, Zhanbo Wang

{"title":"The Expression and Clinicopathological Significance of BRAF V600E and Mucin 6 in Intrahepatic Cholangiocarcinoma: A Retrospective Study.","authors":"Shurui Wu, Meihong Wang, Qinghai Zhou, Haowen Tang, Zhanbo Wang","doi":"10.1177/10668969241266930","DOIUrl":null,"url":null,"abstract":"Aim. The study aims to explore the expression levels and clinicopathological significance of BRAF V600E and mucin 6 in intrahepatic cholangiocarcinoma. Method. Immunohistochemistry for BRAF V600E and mucin 6 was performed in 110 patients with intrahepatic cholangiocarcinoma. Subsequently, a comprehensive review of medical records and clinicopathological analysis was undertaken. Results. BRAF V600E expression was detected in 11 patients (10%); mucin 6 expression was observed in 19 intrahepatic cholangiocarcinoma specimens (17%). Thereafter, Cox regression models indicated that positive expression of either MUC6 positive (hazard ratio = 0.091, 95% confidence interval = 0.034-0.247, P < .001) and BRAF V600E positive (hazard ratio =0.150, 95% confidence interval = 0.058-0.388, P < .001) was significantly linked with longer overall survival for intrahepatic cholangiocarcinoma patients. Conclusion. The study concludes that positive expression of BRAF V600E and mucin 6 could potentially implied significant survival benefits for patients diagnosed with intrahepatic cholangiocarcinoma.","PeriodicalId":14416,"journal":{"name":"International Journal of Surgical Pathology","volume":" ","pages":"399-407"},"PeriodicalIF":0.9000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Surgical Pathology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/10668969241266930","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/8 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PATHOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim. The study aims to explore the expression levels and clinicopathological significance of BRAF V600E and mucin 6 in intrahepatic cholangiocarcinoma. Method. Immunohistochemistry for BRAF V600E and mucin 6 was performed in 110 patients with intrahepatic cholangiocarcinoma. Subsequently, a comprehensive review of medical records and clinicopathological analysis was undertaken. Results. BRAF V600E expression was detected in 11 patients (10%); mucin 6 expression was observed in 19 intrahepatic cholangiocarcinoma specimens (17%). Thereafter, Cox regression models indicated that positive expression of either MUC6 positive (hazard ratio = 0.091, 95% confidence interval = 0.034-0.247, P < .001) and BRAF V600E positive (hazard ratio =0.150, 95% confidence interval = 0.058-0.388, P < .001) was significantly linked with longer overall survival for intrahepatic cholangiocarcinoma patients. Conclusion. The study concludes that positive expression of BRAF V600E and mucin 6 could potentially implied significant survival benefits for patients diagnosed with intrahepatic cholangiocarcinoma.

查看原文本刊更多论文

肝内胆管癌中 BRAF V600E 和 Mucin 6 的表达及临床病理意义：一项回顾性研究

研究目的本研究旨在探讨 BRAF V600E 和粘蛋白 6 在肝内胆管癌中的表达水平和临床病理意义。研究方法对 110 例肝内胆管癌患者进行 BRAF V600E 和粘蛋白 6 免疫组织化学检测。随后，对病历和临床病理分析进行了全面审查。结果11 例患者（10%）检测到 BRAF V600E 表达；19 例肝内胆管癌标本（17%）观察到粘蛋白 6 表达。此后，Cox 回归模型表明，MUC6 阳性表达任一阳性（危险比 = 0.091，95% 置信区间 = 0.034-0.247，P P 结论。该研究得出结论，BRAF V600E 和粘蛋白 6 的阳性表达可能会给确诊为肝内胆管癌的患者带来显著的生存益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Surgical Pathology 医学-病理学

CiteScore

2.10

自引率

0.00%

发文量

198

审稿时长

1 months

期刊介绍： International Journal of Surgical Pathology (IJSP) is a peer-reviewed journal published eight times a year, which offers original research and observations covering all major organ systems, timely reviews of new techniques and procedures, discussions of controversies in surgical pathology, case reports, and images in pathology. This journal is a member of the Committee on Publication Ethics (COPE).